Literature DB >> 23117514

Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees.

Jennifer I Manuel1, Susan M Essock, Yan Wu, Maria Pangilinan, Scott Stroup.   

Abstract

OBJECTIVE: Demographic and clinical factors associated with starting clozapine and other antipsychotics were examined.
METHODS: New York State Medicaid claims from 2008 to 2009 identified individuals with a schizophrenia spectrum disorder, continuous Medicaid eligibility during the study, and at least one clinic service and antipsychotic fill. The sample included individuals who initiated an antipsychotic without any fills for the same medication in the prior 90 days (N=7,035).
RESULTS: Only 144 patients (2%) started on clozapine. They were more likely to be younger, white males who had received services in a state-operated facility, with more hospital admissions and higher total psychiatric costs. African Americans and Hispanics were less likely than whites to start on clozapine. Individuals with substance use disorders were less likely than those without them to start on clozapine.
CONCLUSIONS: Clozapine was rarely prescribed, and problematic disparities were found. Quality improvement efforts are needed to ensure that patients are offered this effective treatment when appropriate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117514     DOI: 10.1176/appi.ps.201100435

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  5 in total

1.  Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Authors:  Daniel C Javitt
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

2.  Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Authors:  Robert O Cotes; David R Goldsmith; Sarah L Kopelovich; Cathy A Lally; Benjamin G Druss
Journal:  Community Ment Health J       Date:  2017-11-10

3.  Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records.

Authors:  Daniela Fonseca de Freitas; India Patel; Giouliana Kadra-Scalzo; Megan Pritchard; Hitesh Shetty; Matthew Broadbent; Rashmi Patel; Johnny Downs; Aviv Segev; Mizanur Khondoker; James H MacCabe; Kamaldeep Bhui; Richard D Hayes
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-03-04       Impact factor: 4.519

4.  Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.

Authors:  Amber Martin; Leona Bessonova; Rachel Hughes; Michael J Doane; Amy K O'Sullivan; Kassandra Snook; Allie Cichewicz; Peter J Weiden; Philip D Harvey
Journal:  Adv Ther       Date:  2022-07-18       Impact factor: 4.070

Review 5.  Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review.

Authors:  Anita Margarette Bayya Ventura; Richard D Hayes; Daniela Fonseca de Freitas
Journal:  Psychol Med       Date:  2022-07-05       Impact factor: 10.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.